These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 24974828)
1. Ewing sarcoma inhibition by disruption of EWSR1-FLI1 transcriptional activity and reactivation of p53. van der Ent W; Jochemsen AG; Teunisse AF; Krens SF; Szuhai K; Spaink HP; Hogendoorn PC; Snaar-Jagalska BE J Pathol; 2014 Aug; 233(4):415-24. PubMed ID: 24974828 [TBL] [Abstract][Full Text] [Related]
2. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma. Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270 [TBL] [Abstract][Full Text] [Related]
3. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma. Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725 [TBL] [Abstract][Full Text] [Related]
4. Ewing sarcoma fusion protein EWSR1/FLI1 interacts with EWSR1 leading to mitotic defects in zebrafish embryos and human cell lines. Embree LJ; Azuma M; Hickstein DD Cancer Res; 2009 May; 69(10):4363-71. PubMed ID: 19417137 [TBL] [Abstract][Full Text] [Related]
5. The clinical heterogeneity of round cell sarcomas with EWSR1/FUS gene fusions: Impact of gene fusion type on clinical features and outcome. Tsuda Y; Zhang L; Meyers P; Tap WD; Healey JH; Antonescu CR Genes Chromosomes Cancer; 2020 Sep; 59(9):525-534. PubMed ID: 32362012 [TBL] [Abstract][Full Text] [Related]
6. Nutlin-3a is a potential therapeutic for ewing sarcoma. Pishas KI; Al-Ejeh F; Zinonos I; Kumar R; Evdokiou A; Brown MP; Callen DF; Neilsen PM Clin Cancer Res; 2011 Feb; 17(3):494-504. PubMed ID: 21098696 [TBL] [Abstract][Full Text] [Related]
7. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1. Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820 [TBL] [Abstract][Full Text] [Related]
8. EWSR1-FLI1 Activation of the Cancer/Testis Antigen FATE1 Promotes Ewing Sarcoma Survival. Gallegos ZR; Taus P; Gibbs ZA; McGlynn K; Gomez NC; Davis I; Whitehurst AW Mol Cell Biol; 2019 Jul; 39(14):. PubMed ID: 31036566 [TBL] [Abstract][Full Text] [Related]
9. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy. Kovar H Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919 [TBL] [Abstract][Full Text] [Related]
16. Targeting the epigenetic readers in Ewing sarcoma inhibits the oncogenic transcription factor EWS/Fli1. Jacques C; Lamoureux F; Baud'huin M; Rodriguez Calleja L; Quillard T; Amiaud J; Tirode F; Rédini F; Bradner JE; Heymann D; Ory B Oncotarget; 2016 Apr; 7(17):24125-40. PubMed ID: 27006472 [TBL] [Abstract][Full Text] [Related]
17. Impairment of p53 acetylation by EWS-Fli1 chimeric protein in Ewing family tumors. Li Y; Li X; Fan G; Fukushi J; Matsumoto Y; Iwamoto Y; Zhu Y Cancer Lett; 2012 Jul; 320(1):14-22. PubMed ID: 22266186 [TBL] [Abstract][Full Text] [Related]
19. EWS-FLI1, EWS-ERG, and EWS-ETV1 oncoproteins of Ewing tumor family all suppress transcription of transforming growth factor beta type II receptor gene. Im YH; Kim HT; Lee C; Poulin D; Welford S; Sorensen PH; Denny CT; Kim SJ Cancer Res; 2000 Mar; 60(6):1536-40. PubMed ID: 10749119 [TBL] [Abstract][Full Text] [Related]
20. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. Kovar H; Amatruda J; Brunet E; Burdach S; Cidre-Aranaz F; de Alava E; Dirksen U; van der Ent W; Grohar P; Grünewald TG; Helman L; Houghton P; Iljin K; Korsching E; Ladanyi M; Lawlor E; Lessnick S; Ludwig J; Meltzer P; Metzler M; Mora J; Moriggl R; Nakamura T; Papamarkou T; Radic Sarikas B; Rédini F; Richter GH; Rossig C; Schadler K; Schäfer BW; Scotlandi K; Sheffield NC; Shelat A; Snaar-Jagalska E; Sorensen P; Stegmaier K; Stewart E; Sweet-Cordero A; Szuhai K; Tirado OM; Tirode F; Toretsky J; Tsafou K; Üren A; Zinovyev A; Delattre O Oncotarget; 2016 Feb; 7(8):8613-24. PubMed ID: 26802024 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]